Provectus to Hold Special Meeting of Stockholders December 16, 2013, in Knoxville, Tennessee
Provectus Pharmaceuticals to Change Name to Provectus Biopharmaceuticals, Inc., Reincorporate in Delaware
November 05, 2013 09:15 AM Eastern Standard Time
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT) ( http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will hold a special meeting of stockholders to vote on the change of the company's name to Provectus Biopharmaceuticals, Inc. and reincorporation of the Company in the State of Delaware from the State of Nevada. The special meeting of stockholders will be held on December 16, 2013 at 4:00 pm EST at the law offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, which is located at 265 Brookview Centre Way, Suite 600, Knoxville, Tennessee 37819.
Dr. Craig Dees, PhD, CEO of Provectus, said, “We believe that these two proposals demonstrate our commitment to protecting our shareholders’ interests and communicating with the markets about our business and our plans for the future.
“Changing our name to ‘Provectus Biopharmaceuticals, Inc.’ will better communicate to the public the current and future nature of our business operations and enable us to better implement our business plan. The new name, if approved, would not affect our business, operations, reporting requirements or stock price but will require a new CUSIP.
“Reincorporation in Delaware will give us more flexibility, clarity and predictability with respect to our corporate governance. The corporate laws in Delaware are more comprehensive, widely-used and extensively interpreted than those of other states, including Nevada. In addition, Delaware provides a recognized body of corporate law that is consistently interpreted by Delaware courts, which we believe will facilitate corporate governance by our officers and directors.” |
